Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer

University of Ulm · 2015
ClinicalTrials.gov · Datasets · License: Public Domain · 2015
Open Source ↗
colorectal-cancercytokines
metastatic colorectal cancer, colorectal cancer, marker-driven, bevacizumab, aflibercept, cytokines, angiogenic factors, caf, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 812057
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.